The CEO and two directors buying shares at current levels near $26 after a strong earnings beat is a rare alignment of insider conviction with positive fundamentals. Monitor for additional insider purchases or a 13D filing. The $83K sale by the SVP & Controller is routine and likely tax-related — ignore it. The cluster amplifies the bullish read from Q2 earnings and suggests management sees the stock as undervalued.
Price Chart
Executive Summary
Four Pfizer insiders traded within a week of Q2 2026 earnings. Chairman & CEO Albert Bourla and two directors made open-market purchases totaling ~$2.96M at ~$25.46-$26.34 per share, while SVP & Controller Jennifer Damico sold $83K worth of shares. The insider buying cluster follows a strong Q2 earnings beat (EPS $0.77 vs $0.68 consensus) and raised full-year revenue guidance, suggesting management sees value at current levels despite the stock's recent weakness.
Key Financial Metrics
Key Facts
- CEO Albert Bourla purchased 38,000 shares at $26.34 for $1.00M on 2026-08-12
- Director Ronald Blaylock purchased 39,200 shares at $25.46 for $999K on 2026-08-05
- Director Mortimer Buckley purchased 37,600 shares at $25.52 for $960K on 2026-08-05
- SVP & Controller Jennifer Damico sold 3,300 shares at $25.40 for $83K on 2026-08-05
- Total open-market purchases by C-suite and directors: $2.96M
- Total insider buying represents ~0.002% of $151.7B market cap — trivial in absolute proportion but significant as a conviction signal from top executives
- Q2 2026 earnings beat consensus by 12.9% on EPS and 4.5% on revenue, with raised full-year guidance
- Stock trades at $26.36, near the purchase prices of all three buying insiders
Financial Impact
Insider purchases of $2.96M at ~$25.46-$26.34 per share represent a strong vote of confidence from the CEO and two directors following a Q2 earnings beat and raised guidance
Risk Factors
- Insider purchases are small relative to $151.7B market cap — not a liquidity signal
- Historical performance on PFE reports shows 0% win rate at T+20 across 7 settled reports, suggesting the stock has been difficult to time
- Pfizer faces ongoing patent cliffs on key products and $4.3B in non-cash impairments from Q2
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-PFE-1786565122998 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 13, 2026 7w ago | Court Ruling | $26.80 $27.72 | ▲ +3.43% | ▲ +5.18% | $27.55 (+2.78%) |
Aug 12, 2026 7w ago | Insider Buy | $26.80 $27.72 | ▲ +3.43% | ▲ +5.18% | $27.55 (+2.78%) |
Aug 12, 2026 7w ago | Insider Cluster | $26.80 $27.72 | ▲ +3.43% | ▲ +5.18% | $27.55 (+2.78%) |
Aug 6, 2026 8w ago | Insider Cluster | $26.20 $28.81 | ▲ +9.95% | ▲ +9.35% | $27.55 (+5.13%) |
Aug 5, 2026 8w ago | Insider Cluster | $26.20 $28.81 | ▲ +9.95% | ▲ +9.35% | $27.55 (+5.13%) |
Aug 4, 2026 8w ago | 8-K | $25.41 $28.55 | ▲ +12.36% | ▲ +13.60% | $27.55 (+8.40%) |
Jul 31, 2026 9w ago | Court Ruling | $25.01 $27.96 | ▼ −11.80% | ▼ −8.81% | $27.55 (−10.14%) |
Jul 24, 2026 10w ago | Court Ruling | $24.54 $28.07 | ▲ +14.38% | ▲ +10.76% | $27.55 (+12.25%) |
Jul 6, 2026 12w ago | ANALYST-DOWNGRADE | $23.72 $25.01 | ▼ −5.44% | ▼ −6.00% | $27.55 (−16.13%) |
Jun 18, 2026 15w ago | 8-K | $25.21 $25.14 | ▼ −0.28% | ▼ −0.81% | $27.55 (+9.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access